Clinical trials: Acute Respiratory Infections
Coronavirus, Covid19
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04838847
- Testing
- CVnCoV Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CureVac
COVID-19
Efficacy of KOVIR Capsule in the Combination Regimen With Background Treatment in COVID-19 Patients
The acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as COVID-19 by the World Health Organization (WHO), is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- NCT05044650
- Testing
- KOVIR capsule combined with background treatment
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- Sao Thai Duong Joint Stock Company
Acute Upper Respiratory Track Infection
Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI
The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo
- Trial name
- Wait and See (NCT01202279)
- Testing
- Guaifenesin
- Where
- 24 sites in United States
- Volunteers
- 1,179 people
- Sponsor
- Reckitt Benckiser Inc.
Healthy Participants
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
- Trial name
- NCT07093580
- Testing
- S-892216-LAI
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Shionogi
Acute Upper Respiratory Tract Infections
Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults
The purpose of this study is: to evaluate safety of the liquid dosage form of Ergoferon in the treatment of acute upper respiratory tract infections in adults; to evaluate clinical efficacy of the liquid dosage form of Ergoferon…
- Trial name
- NCT01765920
- Testing
- Ergoferon
- Where
- 18 sites in Russia
- Volunteers
- 342 people
- Sponsor
- Materia Medica Holding
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Post-COVID-19 Syndrome, COVID-19
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset.
- Conditions
- Post-COVID-19 Syndrome, COVID-19, Dyspnea, Fatigue
- Trial name
- NCT06437210
- Testing
- Viusid Oral Solution
- Where
- Colombia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Catalysis SL
Bronchitis, Chronic
Telithromycin in Acute Exacerbation of Chronic Bronchitis
Study objectives: to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis.
- Trial name
- NCT00288223
- Testing
- Telithromycin
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Sanofi
Acute Respiratory Tract Infection, Flu, Human
Effectiveness of a Nasal Spray on Viral Respiratory Infections
There is no cure for cold or flu, most people recover in about within two weeks. Paracetamol may be used to reduce aches or treat fever, headache, or body aches.
- Conditions
- Acute Respiratory Tract Infection, Flu, Human, COVID-19, Common Cold
- Trial name
- NCT06278324
- Testing
- Nasal Spray HSV Treatment
- Where
- France
- Volunteers
- 76 people
- Sponsor
- CEN Biotech
COVID-19 Respiratory Infection, SARS-CoV-2 Acute Respiratory Disease
Photodynamic Therapy for COVID-19 Prevention
This is a single-center open-label study to evaluate antimicrobial photodynamic therapy (aPDT) for upper airway decolonization in patients presenting with SARS-CoV-2 positive antigen test with mild or no symptoms of COVID-19.
- Trial name
- NCT05184205
- Testing
- Nasal Photodisinfection
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Ondine Biomedical Inc.
COVID-19, SARS-CoV-2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
- Trial name
- NCT04472494
- Testing
- Abatacept
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to moderately severe Pneumocystis pneumonia (PCP).
- Conditions
- Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia, Pneumonia, Pneumocystis Carinii, HIV Infections
- Trial name
- NCT00302341
- Testing
- Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Long COVID
Study of LAU-7b for the Treatment of Long COVID in Adults
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
- Trial name
- ESSOR (NCT05999435)
- Testing
- LAU-7b for 3 cycles
- Where
- 5 sites in Canada
- Volunteers
- 272 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Rhinosinusitis, Rhinosinusitis Acute
The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial of the efficacy and safety of Raphamin in the treatment of acute rhinosinusitis in adult patients.
- Trial name
- NCT06901297
- Testing
- Raphamin
- Where
- 44 sites in Russia
- Volunteers
- 552 people
- Sponsor
- Materia Medica Holding
Respiratory Tract Infections, Urinary Tract Infections in Children
PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)
To evaluate the safety and efficacy of treatment of children with acute bacterial infection disease with Ceftriaxone Sodium and Sulbactam Sodium for Injection in the condition of widely used, and provide the basis of adjusting…
- Trial name
- CRO-SBT (NCT04066621)
- Testing
- Ceftriaxone Sodium and Sulbactam Sodium for Injection
- Volunteers
- 30 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Covid19, Corona Virus Infection
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.
- Conditions
- Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection
- Trial name
- NEUROSIVIR (NCT04480333)
- Testing
- Drug: NA-831 - 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Biomed Industries, Inc.
Coronavirus Disease 2019 (COVID-19) Pneumonia
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in…
- Trial name
- NCT04351152
- Testing
- Lenzilumab, Standard of Care
- Where
- 29 sites in United States, Brazil
- Volunteers
- 520 people
- Sponsor
- Humanigen, Inc.
Coronavirus, Covid19
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
The primary objectives of this study are to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV, and to evaluate the humoral immune responses 14 days…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04860258
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 129 people
- Sponsor
- CureVac
Viral Respiratory Infection
Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection
To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral infection (ARVI).
- Trial name
- NCT04244084
- Testing
- MMH-407
- Where
- 26 sites in Russia
- Volunteers
- 240 people
- Sponsor
- Materia Medica Holding
Urinary Tract Infection, Diabetes Mellitus
Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station
The study objective is to satisfy the testing requirements for the Qualcomm Tricorder XPRIZE Competition. This requires an oversight model using the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station to…
- Conditions
- Urinary Tract Infection, Diabetes Mellitus, Atrial Fibrillation, OSA
- Trial name
- NCT02856633
- Testing
- Vitaliti
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cloud DX Inc.